

# AmpliSens® *Pneumocystis jirovecii* (carinii)- FRT PCR kit



For Professional Use Only

## Instruction Manual

### KEY TO SYMBOLS USED

	Catalogue number		Caution
	Batch code		Contains sufficient for <n> tests
	In vitro diagnostic medical device		Use-by Date
	Version		Consult instructions for use
	Temperature limit		Keep away from sunlight
	Manufacturer	<b>NCA</b>	Negative control of amplification
	Date of manufacture	<b>C-</b>	Negative control of extraction
	Authorized representative in the European Community	<b>C+</b>	Positive control of Amplification
		<b>IC</b>	Internal control

### 1. INTENDED USE

AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit is an in vitro nucleic acid amplification test for qualitative detection of *Pneumocystis jirovecii* (carinii) DNA in the clinical material (bronchoalveolar lavage, sputum, oropharyngeal and tracheal aspirates, lung biopsy material, oropharyngeal washes and swabs) using real-time hybridization-fluorescence detection.

**NOTE:** The results of PCR analysis are taken into account in complex diagnostics of disease.

### 2. PRINCIPLE OF PCR DETECTION

*Pneumocystis jirovecii* (carinii) DNA detection by the polymerase chain reaction (PCR) is based on the amplification of the pathogen genome specific region using specific *Pneumocystis jirovecii* (carinii) primers. In the real-time PCR, the amplified product is detected with the use of fluorescent dyes. These dyes are linked to oligonucleotide probes which bind specifically to the amplified product during thermocycling. The real-time monitoring of fluorescence intensities during the real-time PCR allows the detection of accumulating product without re-opening the reaction tubes after the PCR run.

AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit is a qualitative test based on the use of an endogenous control, the  $\beta$ -globin gene. The DNA target selected as an endogenous internal control is a human genome fragment that is present in sample in a sufficient quantity equivalent to that of cells in the sample. The use of an endogenous internal control makes it possible not only to monitor test stages (DNA extraction and amplification) but also to assess the adequacy of sampling and storage of clinical material.

AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit uses "hot-start", which greatly reduces the frequency of nonspecifically primed reactions. "Hot-start" by the separation of nucleotides and Taq-polymerase using chemically modified polymerase (TaqF). The chemically modified polymerase (TaqF) is activated by heating at 95 °C for 15 min.

The PCR kit contains the system for prevention of contamination by amplicons using the enzyme uracil-DNA-glycosylase (UDG) and dUTP. The enzyme UDG recognizes and catalyzes the destruction of the DNA containing deoxyuridine, but has no effect on DNA containing deoxythymidine. Deoxyuridine is absent in the authentic DNA, but is always present in amplicons, because dUTP is a part of dNTP mixture in the reagents for the amplification. Due to the deoxyuridine containing contaminating amplicons are sensitive to the destruction by UDG before the DNA-target amplification. So the amplicons cannot be amplified.

The enzyme UDG is thermolabile. It is inactivated by heating at temperature above 50 °C. Therefore, UDG does not destroy the target amplicons which are accumulated during PCR. The results of amplification are registered in the following fluorescence channels:

Table 1

Channel for fluorophore	FAM	JOE
DNA-target	DNA fragment of $\beta$ -globin gene (IC Glob)	<i>Pneumocystis jirovecii</i> (carinii) DNA
Target gene	fragment of human $\beta$ -globin gene	gene fragment of <i>Pneumocystis jirovecii</i> (carinii) mitochondrial rRNA large subunit

### 3. CONTENT

AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit is produced in 1 form: variant FRT-50 F R-F2-Mod(RG,iQ,Mx)-CE.

Variant FRT-50 F includes:

Reagent	Description	Volume, ml	Quantity
PCR-mix-1-FRT <i>P.jirovecii</i> / Glob	clear liquid from colorless to light lilac colour	0.6	1 tube
PCR-mix-2-FRT	colorless clear liquid	0.3	1 tube
Polymerase (TaqF)	colorless clear liquid	0.03	1 tube
Positive Control DNA <i>P.jirovecii</i> and human DNA (C+ <i>P.jirovecii</i> and human DNA)	colorless clear liquid	0.1	1 tube
TE-buffer	colorless clear liquid	0.5	1 tube
Negative Control (C-)*	colorless clear liquid	0.5	1 tube

\* must be used in the extraction procedure as a Negative Control of Extraction (see RIBO-prep, K2-9-Et-50-CE protocol).

Variant FRT-50 F is intended for 60 reactions (including controls).

### 4. ADDITIONAL REQUIREMENTS

- Reagent for pretreatment of viscous fluids (sputum, bronchoalveolar lavage).
- Saline solution or PBS (137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM sodium monophosphate, and 2 mM potassium diphosphate (pH 7.5 ± 0.2)) for pretreatment of sputum and biopsy material.
- Transport medium.
- DNA extraction kit.
- Disposable powder-free gloves and a laboratory coat.
- Pipettes (adjustable).
- Sterile pipette tips with aerosol filters (up to 200  $\mu$ l).
- Tube racks.
- Vortex mixer.
- Desktop centrifuge with rotor for 2-ml reaction tubes.
- PCR box.
- Real-time instruments (for example, Rotor-Gene 3000/6000 (Corbett Research, Australia); Rotor-Gene Q (QIAGEN, Germany), iCycler iQ5 (Bio-Rad, USA), Mx3000P (Stratagene, USA)).
- Disposable polypropylene tubes:
  - a) tightly closed or screwed 1.5-ml tubes for pretreatment
  - b) tightly closed or screwed 2.0-ml tubes for pretreatment
  - c) screwed or tightly closed 1.5-ml tubes for reaction mixture preparation.
  - d) thin-walled 0.2-ml PCR tubes with domed caps if a plate-type instrument is used;
  - e) thin-walled 0.2-ml PCR tubes with flat caps or strips of four 0.1-ml Rotor-Gene PCR tubes if a rotor-type instrument is used.
- Refrigerator for 2–8 °C.
- Deep-freezer at the temperature from minus 24 to minus 16 °C.
- Reservoir for used tips.

### 5. GENERAL PRECAUTIONS

The user should always pay attention to the following:

- Use sterile pipette tips with aerosol barriers and use a new tip for every procedure.
- Store all extracted positive material (specimens, controls and amplicons) away from all other reagents and add it to the reaction mix in a distantly separated facility.
- Thaw all components thoroughly at room temperature before starting an assay.
- When thawed, mix the components and centrifuge briefly.
- Use disposable protective gloves and laboratory cloths, and protect eyes while samples and reagents handling. Thoroughly wash hands afterwards.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all specimens and unused reagents in accordance with local regulations.
- Samples should be considered potentially infectious and handled in biological cabinet in compliance with appropriate biosafety practices.
- Clean and disinfect all samples or reagents spills using a disinfectant, such as 0.5 % sodium hypochlorite or another suitable disinfectant.
- Avoid samples and reagents contact with the skin, eyes, and mucous membranes. If these solutions come into contact, rinse the injured area immediately with water and seek medical advice immediately.
- Safety Data Sheets (SDS) are available on request.
- Use of this product should be limited to personnel trained in DNA amplification techniques.
- Workflow in the laboratory must be one-directional, beginning in the Extraction Area and moving to the Amplification and Detection Area. Do not return samples, equipment and reagents in the area where the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

## 6. SAMPLING AND HANDLING

**NOTE:** Obtaining samples of biological materials for PCR-analysis, transportation, and storage are described in the manufacturer's handbook [1]. It is recommended that this handbook is read before starting work.

**AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** is intended for analysis of *Pneumocystis jirovecii* (carinii) DNA extracted with DNA extraction kits from the clinical material (bronchoalveolar lavage, sputum, oropharyngeal and tracheal aspirates, lung biopsy material, oropharyngeal washes and swabs)

6.1 **Bronchoalveolar lavage, oropharyngeal and tracheal aspirates** samples should be placed into a sterile disposable tube or container. The material must be pretreated for the analysis. Thoroughly resuspend the sample and transfer 1 ml of the material into an Eppendorf tube using a filter tip. Centrifuge the tube for 10 min at 7,000 g (8,000-10,000 rpm in a 24-well centrifuge or 10,000–13,000 rpm in a 12-well centrifuge). Carefully remove and discard the supernatant using a filter tip and leaving 200 µl of the liquid on the sediment. Resuspend the sample on vortex.

Bronchoalveolar lavage, oropharyngeal and tracheal aspirates and pretreated material can be stored:

- at 2–8 °C for 1 day;
- at the temperature not more than minus 16 °C for 7 days;
- at the temperature not more than minus 68 °C for a long time.

**NOTE:** Only one freeze–thaw cycle of clinical material is allowed.

6.2 **Sputum.** Sputum is collected into a sterile disposable container after preliminarily rinsing the mouth with water. The material must be pretreated for the analysis. Add **Mucolysin** reagent [REF] 180-CE to the sputum sample at a ratio of 5:1 (5 volume of Mucolysin per 1 volume of sputum) using graduation on the container. While sputum is liquefied (20–30 min), shake the container occasionally. Transfer 1 ml of the sample into a 1.5-ml Eppendorf tube using a filter tip and centrifuge it at 7,000 g (8,000–10,000 rpm in a 24-well centrifuge or 10,000–13,000 rpm in a 12-well centrifuge) for 10 min. Remove and discard the supernatant using a vacuum aspirator. Resuspend the pellet in 100 µl of PBS (or saline) and use it for DNA extraction.

Samples can be stored:

- at 2–8 °C for 3 days;
- at the temperature not more than minus 16 °C for 7 days;
- at the temperature not more than minus 68 °C for a long time.

**NOTE:** Only one freeze–thaw cycle of clinical material is allowed.

6.3 **Biopsy and autopsy material samples.** Tissue samples are excised from the areas of presumable pathogen location, from damaged tissue, or from areas adjacent to the damaged areas. Tissue fragments not more than 5 mm in diameter are placed in a sterile disposable 2-ml Eppendorf tube containing 0.5 ml of **Transport Medium with Mucolytic Agent** [REF] 952-CE; [REF] 953-CE.

Samples can be stored:

- at room temperature for 6 h;
- at 2–8 °C for 3 days;
- at the temperature not more than minus 16 °C for a long time.

For the analysis of larger fragments of tissues, place a sample in a sterile porcelain mortar. Add an equal volume of saline or PBS. Thoroughly homogenize the sample with a pestle. Transfer 100 µl of the prepared suspension to a sterile tube for DNA extraction. Samples can be stored at the temperature not more than minus 16 °C.

6.4 **Oropharyngeal washes and swabs** are obtained with a sterile probe and placed in a tube with **Transport Medium for Storage and Transportation of Respiratory Swabs** [REF] 959-CE; [REF] 957-CE; [REF] 958-CE.

Samples can be stored:

- at 2–8 °C for 1 day;
- at the temperature not more than minus 68 °C for 1 year.

## 7. WORKING CONDITIONS

**AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** should be used at 18–25 °C.

## 8. PROTOCOL

### 8.1. DNA extraction

It is recommended to use the following nucleic acid extraction kits:

- **RIBO-prep**, [REF] K2-9-EI-50-CE.

In the extraction procedure it is necessary to carry out the control reaction as follows:

- C– — Add **100 µl of Negative Control (C–)** to the tube labeled C– (Negative Control of Extraction).

**NOTE:** Extract DNA according to the manufacturer's protocol.

### 8.2. Preparing PCR

#### 8.2.1 Preparing tubes for PCR

The type of tubes depends on the type of PCR real-time instrument.

Use disposable filter tips for adding reagents, DNA and control samples into tubes.

The total reaction volume is **25 µl**, the DNA sample volume is **10 µl**.

1. Preparation of **PCR-mix-2-FRT** and **polymerase (TaqF)** mixture:

Transfer the entire content of the tube (**30 µl**) with **polymerase (TaqF)** into the tube containing **300 µl of PCR-mix-2-FRT** and vortex carefully avoiding foaming. Label the tube by the date of preparation.

The prepared mixture is intended for analysis of 60 samples.

Store the prepared mixture at 2–8 °C for 3 months and use it as needed.

**NOTE:** If the prepared mixture cannot be utilized within 3 months, prepare the mixture for a smaller number of reactions (for example, mix **150 µl of PCR-mix-2-FRT** and **15 µl of polymerase (TaqF)** (this mixture is intended for 30 reactions).

2. Prepare the reaction mixture. Note that, for testing even one experimental DNA sample, two controls of amplification (one positive and one negative) should be carried out. It is recommended to mix reagents for an even number of reactions to ensure more accurate dispensing.

3. Mix in a new tube **PCR-mix-1-FRT *P.jirovecii* / Glob** and the mixture of **PCR-mix-2-FRT** and **polymerase (TaqF)**, which was prepared earlier. Prepare the required amount of the mixture proceeding from the volumes required for one reaction:

- **10 µl of PCR-mix-1-FRT *P.jirovecii* / Glob;**
- **5 µl of the mixture of PCR-mix-2-FRT and polymerase (TaqF).**

4. Calculate the volume of the reaction mixture for the required number of reactions including the testing of the clinical and control samples according to the scheme of the reaction mixture preparation (see Table 2).

Scheme of reaction mixture preparation

Table 2

Number of clinical samples including controls	PCR-mix-1-FRT <i>P.jirovecii</i> / Glob, µl	PCR-mix-2-FRT + polymerase (TaqF), µl
1	40	20
2	50	25
3	60	30
4	70	35
5	80	40
6	90	45
7	100	50
8	110	55
9	120	60
10	130	65
11	140	70
12	150	75
13	160	80
14	170	85
15	180	90
16	190	95
17	200	100
18	210	105
19	220	110
20	230	115
21	240	120
22	250	125
23	260	130
24	270	135
25	280	140
26	290	145
27	300	150
28	310	155
29	320	160
30	330	165
31	340	170
32	350	175
33	360	180
34	370	185

5. Take the required number of tubes for amplification of DNA extracted from clinical and control samples. The type of tubes depends on the PCR instrument used. Add 15 µl of the prepared reaction mixture into each tube.

6. Add **10 µl of DNA** samples obtained at the DNA extraction stage into the prepared tubes with the reaction mixture.

7. Carry out the control amplification reactions:

- NCA** — Add **10 µl of TE-buffer** to the tube labeled NCA (Negative Control of Amplification).
- C+** — Add **10 µl of Positive Control DNA *P.jirovecii* and human DNA (C+*P.jirovecii* and human DNA)** to the tube labeled C+ (Positive Control of Amplification).
- C–** — Add **10 µl of the sample extracted from the Negative Control (C–) reagent** to the tube labeled C– (Negative control of Extraction).

### 8.2.2. Amplification

1. Create a temperature profile on your instrument as follows:

Table 3

Step	Rotor-type instruments <sup>1</sup>			Plate-type instruments <sup>2</sup>		
	Temperature, °C	Time	Cycles	Temperature, °C	Time	Cycles
1	95	15 min	1	95	15 min	1
2	95	5 s	5	95	5 s	5
	60	20 s		60	20 s	
	72	15 s		72	15 s	
3	95	5 s	40	95	5 s	40
	60	20 s fluorescent signal detection		60	30 s fluorescent signal detection	
	72	15 s		72	15 s	

Fluorescent signal is detected in the channels for the FAM and JOE fluorophores (other channels are enabled if several tests are simultaneously carried out in a single run).

2. Adjust the fluorescence channel sensitivity according to the *Important Product Information Bulletin* and Guidelines [2].

3. Insert tubes into the reaction module of the device.

4. Run the amplification program with fluorescence detection.

5. Analyze results after the amplification program is completed.

<sup>1</sup> For example, Rotor-Gene 3000, Rotor-Gene 6000, Rotor-Gene Q.

<sup>2</sup> For example, iCycler iQ5, Mx3000P.

## 9. DATA ANALYSIS

Analysis of results is performed by the software of the real-time PCR instrument used by measuring fluorescence signal accumulation in two channels:

- The signal of the **β-globin gene DNA (Internal Control Glob (IC Glob))** amplification product is detected in the channel for the FAM fluorophore.
- The signal of the ***Pneumocystis jirovecii* (carinii) DNA** amplification product is detected in the channel for the JOE fluorophore.

Results are interpreted by the crossing (or not-crossing) the fluorescence curve with the threshold line set at the specific level that corresponds to the presence (or absence) of a Ct value of the DNA sample in the corresponding column of the results grid.

Principle of interpretation is the following:

- *Pneumocystis jirovecii* (carinii) DNA is **detected** in a sample if the Ct value determined in the results grid in the channel for the JOE fluorophore is less than the specified boundary Ct value. Moreover, the fluorescence curve should cross the threshold line in the area of the exponential growth of fluorescence.
- *Pneumocystis jirovecii* (carinii) DNA is **not detected** in a sample if the Ct value is not determined (absent) in the results grid (the fluorescence curve does not cross the threshold line) in the channel for the JOE fluorophore, whereas the Ct value determined in the channel for the FAM fluorophore is less than the specified boundary Ct value.
- The result is **invalid** if the Ct value of a sample in the channel for the JOE fluorophore is not determined (absent) or greater than the boundary Ct value specified in the *Important Product Information Bulletin*. In such cases, the PCR analysis should be repeated.
- The result is **equivocal** if the Ct value in the channel for the JOE fluorophore exceeds the boundary Ct value specified in the *Important Product Information Bulletin*. The PCR analysis of this sample should be repeated in duplicate. If a reproducible positive Ct value is obtained, the sample is considered positive. If the result is not reproduced in duplicate, the sample is considered equivocal.

**NOTE:** Boundary Ct values are specified in the *Important Product Information Bulletin* enclosed to the PCR kit. See also Guidelines [2]

The result of the analysis is considered reliable only if the results obtained for Positive and Negative Controls of amplification as well as for the Negative Control of extraction are correct (see Table 4).

Table 4

Results for controls

Control	Stage for control	Ct value in channel for fluorophore	
		FAM	JOE
C–	DNA extraction	Absent	Absent
NCA	PCR	Absent	Absent
C+	PCR	<boundary value	<boundary value

## 10. TROUBLESHOOTING

Results of analysis are not taken into account in the following cases:

1. If the Ct value is determined for the Negative Control of extraction (C–) and for the Negative Control of Amplification (NCA) in the channels for the FAM and JOE fluorophores, it indicates the contamination of reagent or samples. The PCR analysis (beginning with the DNA extraction stage) should be repeated for all samples in which *Pneumocystis jirovecii* (carinii) DNA was detected.
2. If the Ct value is absent or exceeds the boundary Ct value for the Positive Control of Amplification (C+), the PCR analysis of all samples should be repeated starting from the PCR stage.
3. If the Ct values for the clinical samples in the channel for the FAM fluorophore are absent in the results grid, this suggests the extraction stage failure. The PCR analysis of these samples should be repeated starting from extraction stage.
4. If Ct values for the analyzed sample exceed the boundary Ct values in the channels for the FAM and JOE fluorophores, the analysis of this sample should be repeated starting from the DNA extraction stage. High Ct values can be due to the loss of DNA or the presence of inhibitors

If you have any further questions or if encounter problems, please contact our Authorized representative in the European Community.

## 11. TRANSPORTATION

**AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** should be transported at 2–8 °C for no longer than 5 days.

## 12. STABILITY AND STORAGE

All components of the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** are to be stored at 2–8 °C when not in use (except for polymerase (TaqF), PCR-mix-2-FRT and PCR-mix-1-FRT *P.jirovecii* / Glob). All components of the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** are stable until the expiry date stated on the label. The shelf life of reagents before and after the first use is the same, unless otherwise stated.

**NOTE:** Polymerase (TaqF), PCR-mix-2-FRT and PCR-mix-1-FRT *P.jirovecii* / Glob are to be stored at the temperature from minus 24 to minus 16 °C when not in use.

**NOTE:** PCR-mix-1-FRT *P.jirovecii* / Glob is to be kept away from light.

## 13. SPECIFICATIONS

### 13.1. Sensitivity

The analytical sensitivity of the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** is given the table below.

Clinical material	DNA extraction kit	Analytical sensitivity, copies/ml
Bronchoalveolar lavage; sputum; oropharyngeal and tracheal aspirates; oropharyngeal washes and swabs; lung biopsy material	RIBO-prep	500

### 13.2. Specificity

The analytical specificity of **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** is ensured by the selection of specific primers and probes as well as stringent reaction conditions. The primers and probes have been checked for possible homologies to all sequences published in gene banks by sequence comparison analysis.

Nonspecific reactions were absent in tests of human DNA samples and DNA samples of the following organisms: fungi (*Penicillium auzontzag*, *P.brevicompactum*; *Ulocladium boffocytus*; *Mucor racemosus*, *M.plumbeus*; *Aspergillus versicolor*, *A.niger*, *A.flavus*, *A.fumigatus*; *Cryptococcus neoformans*), viruses (*Epstein-Barr virus*; *Herpes simplex virus* types I and II; *Herpes virus* types 6 and 8, *Varicella-Zoster virus*, *Parvovirus B19*, and others), bacteria (*Streptococcus pyogenes*, *S.agalactiae*; *Staphylococcus aureus*, and others).

The clinical specificity of the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** was confirmed in laboratory clinical trials.

## 14. REFERENCES

1. Handbook "Sampling, Transportation, and Storage of Clinical Material for PCR diagnostics", developed by Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service for Surveillance on Consumers' Rights Protection and Human Well-Being.
2. Guidelines to the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** for qualitative detection of *Pneumocystis jirovecii* (carinii) DNA in the clinical material by the polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection developed by Federal Budget Institute of Science "Central Research Institute for Epidemiology".

## 15. QUALITY CONTROL

In compliance with Federal Budget Institute of Science "Central Research Institute for Epidemiology" ISO 13485-Certified Quality Management System, each lot of the **AmpliSens® *Pneumocystis jirovecii* (carinii)-FRT PCR kit** has been tested against predetermined specifications to ensure consistent product quality.

List of Changes Made in the Instruction Manual

VER	Location of changes	Essence of changes
27.12.10 RT	Cover page	The phrase "For Professional Use Only" was added
	Intended use	The phrase "The results of PCR analysis are taken into account in complex diagnostics of disease" was added.
	Content	New sections "Working Conditions" and "Transportation" were added The "Explanation of Symbols" section was renamed to "Key to Symbols Used"
	Stability and Storage	The information about the shelf life of open reagents was added Information that PCR-mix-1-FRT <i>P.jirovecii</i> / Glob is to be kept away from light was added
	Key to Symbols Used	The explanation of symbols was corrected
30.06.11 LA	Cover page, text	The name of Institute was changed to Federal Budget Institute of Science "Central Research Institute for Epidemiology"
10.01.12 VV	Page footer	Catalogue number R-F2-Mod(RG,iQ,Mx)-CE was added
	Throughout the text	A new format of the reagent kit was introduced
		Names of reagents were changed The volume of PCR-mix-1 was changed
13.10.15 ME	Text	Corrections according to the template
	8.2.1 Preparing tubes for PCR	Scheme of reaction mixture preparation was added from the Appendix
14.02.19 TA	14. References	The reference to Guidelines was added
	2. Principle of PCR detection	The information about the enzyme UDG was added.
13.03.19 EM	3. Content	The colour of the reagent was specified
12.08.20 KK	Through the text	The text formatting was changed
	Footer	The phrase "Not for use in the Russian Federation" was added
	2. Principle of PCR detection	The table with targets was added
11.03.21 MM	—	The name, address and contact information for Authorized representative in the European Community was changed

**AmpliSens®**



Ecoli Dx, s.r.o., Purkyňova 74/2  
110 00 Praha 1, Czech Republic  
Tel.: +420 325 209 912  
Cell: +420 739 802 523



Federal Budget Institute of Science "Central Research Institute for Epidemiology"  
3A Novogireevskaya Street  
Moscow 111123 Russia